Last $2.25 USD
Change Today 0.00 / 0.00%
Volume 192.0
ANTB On Other Exchanges
Symbol
Exchange
OTC US
As of 11:56 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

antriabio inc (ANTB) Snapshot

Open
$2.25
Previous Close
$2.25
Day High
$2.25
Day Low
$2.25
52 Week High
05/1/14 - $4.00
52 Week Low
12/15/14 - $0.90
Market Cap
49.5M
Average Volume 10 Days
3.3K
EPS TTM
$-1.15
Shares Outstanding
22.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANTRIABIO INC (ANTB)

Related News

No related news articles were found.

antriabio inc (ANTB) Related Businessweek News

No Related Businessweek News Found

antriabio inc (ANTB) Details

AntriaBio, Inc., a preclinical stage company, focuses on developing novel therapeutic products for the diabetes market. Its lead product candidate is AB101, a human recombinant insulin for use in patients with type 1 and type 2 diabetes who require basal insulin replacement therapy for the control of hyperglycemia. The company was founded in 2010 and is headquartered in Menlo Park, California.

5 Employees
Last Reported Date: 11/26/14
Founded in 2010

antriabio inc (ANTB) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $361.2K
Advisor
Total Annual Compensation: --
Chief Scientific Officer
Total Annual Compensation: $365.2K
Compensation as of Fiscal Year 2014.

antriabio inc (ANTB) Key Developments

AntriaBio, Inc. Announces Appointment of Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development

AntriaBio, Inc. announced that Dr. Hoyoung Huh, one of the company's co-founders and member of the Board of Directors will expand his role to Chair the company's business development efforts, product pipeline strategy, and Scientific Advisory Board. In his expanded role, Dr. Huh will partner with his long-time colleague, Nevan Elam, the company's Chairman and Chief Executive Officer, as well as the Chief Scientific Officer, Dr. Sankaram Mantripragada.

AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species

AntriaBio, Inc. announced that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment. AntriaBio is currently engaged in additional studies, including ongoing toxicology studies that would support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101 and the subsequent launch of a clinical study in type 1 diabetes patients this year.

AntriaBio, Inc. announced delayed annual 10-K filing

On 09/30/2014, AntriaBio, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTB:US $2.25 USD 0.00

ANTB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTB.
View Industry Companies
 

Industry Analysis

ANTB

Industry Average

Valuation ANTB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTRIABIO INC, please visit www.antriabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.